美银证券报告指，翰森制药(03692.HK) 的阿美替尼(almonertinib)、氟马替尼(flumatinib)、聚乙二醇洛塞那肽(PEG-loxenatide)、艾米替诺福韦片(tenofovir amibufenamide)分别录得销售额2.049亿元人民币、5,190万元人民币、2,000万元人民币和7,280万元人民币，按年变化分别为44.9%、57.4%、-31.0%、28.3%，...
Source Link美银证券报告指，翰森制药(03692.HK) 的阿美替尼(almonertinib)、氟马替尼(flumatinib)、聚乙二醇洛塞那肽(PEG-loxenatide)、艾米替诺福韦片(tenofovir amibufenamide)分别录得销售额2.049亿元人民币、5,190万元人民币、2,000万元人民币和7,280万元人民币，按年变化分别为44.9%、57.4%、-31.0%、28.3%，...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.